← SAB Biotherapeutics, Inc. (SABS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SAB Biotherapeutics, Inc. (SABS)
Biological Products, (No Diagnostic Substances) · market cap $309M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
SAB Biotherapeutics (SABS) is a ~$288M market-cap biologics company with 63 employees running two Phase 2 programs: SAB-176 for Influenza A H1N1 and High Dose SAB-142 for Type 1 Diabetes. The company is in acute financial distress with only $20.5M cash and an estimated 4.3-month runway, zero revenue in the most recent fiscal year, and elevated dilution risk flagged at 28%.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SAB-176 | Phase 2 | Influenza A H1N1 |
| High Dose SAB-142 | Phase 2 | Type 1 Diabetes |
Price & technical context
3-month
-21.9%
6-month
-20.9%
12-month
+52.2%
52-wk range
$1.98–$4.59
vs 50-day MA
-14.9%
vs 200-day MA
-19.1%
Realized vol
63.4%
Max drawdown
-76.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SABS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.